This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Lithium Treatment Effects on the Neuropsychological Functioning of Patients With Bipolar I Disorder

Carlos López-Jaramillo, MD, Msc; Juan Lopera-Vásquez, PsyD; Jorge Ospina-Duque, MD; Jenny Garcí­a, MD, Msc; Aurora Gallo, PsyD; Vladimir Cortez, MD; Carlos Palacio, MD, Msc; Carla Torrent, PsyD; Anabel Martí­nez-Arán, PhD; and Eduard Vieta, MD, PhD

Published: March 23, 2010

Article Abstract

Objective: To determine if medication plays a major role in cognitive impairment in bipolar disorder and if regular treatment with lithium influences the cognitive performance of a group of euthymic patients with bipolar I disorder.

Method: Cognitive performance was assessed using neuropsychological tests of attention, memory, and executive function on 60 subjects: 20 euthymic bipolar I patients with no medication intake, 20 euthymic bipolar I patients who were following regular treatment with lithium carbonate monotherapy, and a third group of 20 control healthy subjects. The subjects were evaluated from January 2005 to October 2006. Patients were diagnosed using DSM-IV criteria for bipolar disorder.

Results: Compared to the healthy group, bipolar I patients had significantly lower performance on episodic verbal and visual-verbal memory regardless of their medication status. No significant cognitive performance differences were found between the two groups of patients with bipolar disorder, suggesting that lithium therapy had no deleterious effects on cognition.

Conclusion: Patients with bipolar I disorder have verbal memory deficits that are not explained by medication or by lithium monotherapy, but by the condition itself.

J Clin Psychiatry 2010;71(8):1055-1060

Submitted: July 18, 2008; accepted February 28, 2009.

Online ahead of print: March 23, 2010 (doi:10.4088/JCP.08m04673yel).

Corresponding author: Carlos López-Jaramillo, MD, Msc, Department of Psychiatry, School of Medicine, Universidad de Antioquia, Cra 43A No 1-50 Of 954, Medellí­n, Colombia (clopez@medicina.udea.edu.co).

Volume: 71

Quick Links: Bipolar Disorder

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...